Teva Completes ‘Digihaler Family’
After Announcing Two Further Digital Inhaler Launches
Teva has completed its portfolio of digital inhalers by launching a further two products, AirDuo Digihaler (fluticasone propionate/salmeterol) and ArmonAir Digihaler (fluticasone propionate), in the US. The pair join the firm’s previously launched ProAir Digihaler (albuterol sulfate).
You may also be interested in...
To boost the technology used in its digihaler family of inhalers, Teva has partnered with Amazon Web Services and Onica, a Rackspace Technology company. With this collaboration, Teva aims to protect patients’ information and ensure data security.
Teva’s innovative asthma device, Aermony RespiClick (fluticasone propionate inhalation powder), will be accessible to over 3.8 million affected asthmatic patients in Canada in three dose options.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.